Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Eli Lilly Q1 revenue jumps 56% to $19.8B; raises 2026 revenue and EPS guidance

LLY

$1,158.50

+$1.87 +0.16%

Eli Lilly Q1 revenue jumps 56% to $19.8B; raises 2026 revenue and EPS guidance

Company Fundamentals

30 Apr 2026

PRNewsWire

View Source

Bullish

Eli Lilly reported a 56% revenue increase to $19.8 billion in Q1 2026, driven mainly by volume growth of key products like Mounjaro and Zepbound despite lower prices. Earnings per share rose sharply by 170% on a reported basis to $8.26. The company also raised its full-year 2026 revenue guidance to $82-85 billion and non-GAAP EPS guidance to $35.50-37.00. Significant milestones include FDA approval of Foundayo for obesity and multiple pipeline and acquisition advances, positioning Lilly for continued growth.

More News (LLY)

Eli Lilly stock could grow 76% in 3 years driven by blockbuster drugs and new sales channels.

Eli Lilly's stock is projected to grow about 76% over the next three years, reaching around $2,091 per share. This growth is fueled by strong revenue increases from blockbuster drugs like Mounjaro and Zepbound, which contributed $6.7 billion in new r...

Analyst Insights

Bullish

1 day ago